Prevalence and causes of macular edema and its correlation: an observational study

  • Ishtpreet Mann
  • Rajwinder Kaur Gian Sagar Medical College and Hospital, Banur, Rajpura
  • Balbir Khan
  • Prithpal S Matreja
  • R N Bhatnagar
Keywords: Macular edema, Diabetes mellitus, vision, floater, retinopathy

Abstract

Background: Macular edema occurs when fluid and protein deposits collect on or under the macula of eye and causes it to thicken and swell. If left untreated, macular edema can cause severe vision loss and even blindness. Diabetic retinopathy is the major cause of macular edema. The data on Indian populations is lacking hence we have designed this study to find out the prevalence and causes of Macular edema and to study its correlation.Methods: This prospective, observational study was conducted in the Department of ophthalmology. The patients with best corrected visual acuity loss within the last 6 months of evolution, caused by the macular edema as stated by investigator´s judgement and those who gave informed consent were included in the study. A total of 50 patients were included in the study after signing the informed consent.Results: The results showed that macular edema occurs mostly in old age and diabetes mellitus is the most common cause of macular edema followed by a combination of hypertension and diabetes. The least common causes include ARMD, glaucoma, CSME and frosted branch angiitis. Diabetics showed a greater problem of floaters as compared to non diabetics. Diabetics showed a gradual and partial vision loss which was more common in right eye. Rests of the results were statistically insignificant.Conclusion: It was observed in our study that diabetes is the most common cause of macular edema. It causes gradual and partial vision loss.

Author Biography

Rajwinder Kaur, Gian Sagar Medical College and Hospital, Banur, Rajpura
Assistant professorDepartment of opthalmology 

References

1. Macular edema (available at url. http://en.wikipedia.org/wiki/Macular_edema) (Last Assessed on 13th October, 2014)

2. Macular edema symptoms (Available at url.http://www.geteyesmart.org/eyesmart/diseases/macular-edema-symptoms.cfm) (Last Assessed on 13th October, 2014)

3. Petrella RJ, Blouin J, Davies B, Barbeau M. Prevalence, demographic, and treatment characteristic of visual impairment due to diabetic macular edema in a representative Canadian cohort. Journal of Ophthalmology 2012, Article ID 159167. http://dx.doi.org/10.1155/2012/159167 (Available at url. http://www.hindawi.com/journals/joph/2012/159167/) (Last Assessed on 13th October, 2014)

4. Cunha-Vaz J. Macular Edema. Available at url. http://www.ema.europa.eu/docs/en_GB/document_library/Presentation/2011/11/WC500117604.pdf (Last Assessed on 13th October, 2014)

5. Causes of retinal edema (Available at url. http://www.rightdiagnosis.com/r/retinal_edema/causes.htm#commoncause) (Last Assessed on 13th October, 2014)

6. Liu X, Zhou X, Wang Z, Li T, Jiang B. Intravitreal bevacizumab with or without triamcinolone acetonide for diabetic macular edema: A meta-analysis of randomized controlled trials. Chin Med J (Engl) 2014; 127: 3471-6. Available at url. http://www.ncbi.nlm.nih.gov/pubmed/25269916

7. Papadia M, Misteli M, Jeannin B, Herbort CP. The influence of anti-VEGF therapy on present day management of macular edema due to BRVO and CRVO: a longitudinal analysis on visual function, injection time interval and complications. Int Ophthalmol 2014 [Epub ahead of print]. Available at url. http://www.ncbi.nlm.nih.gov/pubmed/25245600

8. Ferraz DA, Vasquez LM, Preti RC, Motta A, Sophie R, Bittencourt Mg, et.al. A randomized controlled trial of panretinal photocoagulation with and without intravitreal ranibizumab in treatment-naive eyes with non-high-risk proliferative diabetic retinopathy. Retina 2014 [Epub ahead of print]. Available at url. http://www.ncbi.nlm.nih.gov/pubmed/25272318

9. FDA Green-Lights Genentech’s Lucentis for Macular Edema following Retinal Vein Occlusion. Available at url: http://www.genengnews.com/gen-news-highlights/fda-green-lights-genentech-s-lucentis-for-macular-edema-following-retinal-vein-occlusion/81243570/ (Last Assessed on 13th October, 2014)

10. Iluvien gains marketing authorization in Portugal for chronic DME. Available at url:http://www.healio.com/ophthalmology/regulatory-legislative/news/online/ %7Be6142093-e832-4b21-a6b1-bd25e25e476c%7D/iluvien-gains-marketing-authorization-in-portugal-for-chronic-dme (Last Assessed on 13th October, 2014)
Published
2015-11-12
Issue
Vol 2 No 4 (2015)
Section
Original Article

Authors who publish with this journal agree to the following terms:

  1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).